<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236872</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0703/91 Acute</org_study_id>
    <nct_id>NCT01236872</nct_id>
  </id_info>
  <brief_title>The Acute Effect of Beetroot Juice in Normal and Hypertensive Subjects</brief_title>
  <official_title>The Acute Effect of Beetroot Juice on Circulating Nitrate and Nitrite Levels and Blood Pressure in Normotensives and Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inorganic nitrate can be converted to nitrite and thence nitric oxide in humans. Nitric oxide&#xD;
      is normally produced by the inner lining of blood vessels and helps keep blood vessels open&#xD;
      and therefore blood pressure lower. In subjects with high blood pressure, the inner lining of&#xD;
      the blood vessels does not function adequately. The investigators wish to investigate whether&#xD;
      elevating systemic levels of inorganic nitrate (through provision of dietary nitrate-rich&#xD;
      vegetables) can elevate levels of nitrate/nitrite in hypertensive subjects, and whether this&#xD;
      has a beneficial effect on blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in circulating nitrate/nitrite/cGMP levels</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>3hours</time_frame>
    <description>pulse wave velocity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Beetroot juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250ml beetroot juice ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250ml low-nitrate water placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beetroot juice</intervention_name>
    <description>250ml once of beetroot juice</description>
    <arm_group_label>Beetroot juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>250ml once of low-nitrate mineral water</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male and females between 18 and 85 years of age, inclusive.&#xD;
&#xD;
          2. To be eligible, female subjects will be required to state that they are not pregnant,&#xD;
             and will not become pregnant during the course of the study.&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 40 kg/m2&#xD;
&#xD;
          4. A signed and dated written informed consent prior to admission to the study&#xD;
&#xD;
          5. The subject is able to understand and comply with protocol requirements, instructions&#xD;
             and protocol-stated restrictions.&#xD;
&#xD;
          6. Grade 1 hypertensive SBP 140-159 or DBP 90-99 on no anti-hypertensives, no target&#xD;
             organ damage (TOD), low cardiovascular disease (CVD) risk&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of symptomatic coronary artery disease, stroke, or other known atherosclerotic&#xD;
             disease.&#xD;
&#xD;
          2. History of chronic viral hepatitis (including presence of hepatitis B surface antigen&#xD;
             or hepatitis C antibody), or other chronic hepatic disorders.&#xD;
&#xD;
          3. History of increased liver function tests (ALT, AST) due to acute or chronic liver&#xD;
             conditions, 3x above the upper limit of normal or bilirubin 1.5x above the upper limit&#xD;
             of normal at screening.&#xD;
&#xD;
          4. Renal impairment with creatinine clearance (eGFR) of &lt;50 ml/min at screening.&#xD;
&#xD;
          5. Current poorly controlled diabetes mellitus, defined as HbA1c &gt;10% at Screen.&#xD;
&#xD;
          6. Subjects with LDLc, &gt;7.5 mmol/l. Fasting TG level &gt;6mmol/l.&#xD;
&#xD;
          7. History of heart failure defined as NYHA class II - IV or those with known severe LV&#xD;
             dysfunction (EF&lt;30%) regardless of symptomatic status&#xD;
&#xD;
          8. History of malignancy within the past 5 years, other than non-melanoma skin cancer.&#xD;
&#xD;
          9. Current life-threatening condition other than vascular disease (e.g., very severe&#xD;
             chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent&#xD;
             a subject from completing the study.&#xD;
&#xD;
         10. Alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
         11. Use of an investigational device or investigational drug within 30 days or 5&#xD;
             half-lives (whichever is the longer) preceding the first dose of study medication.&#xD;
&#xD;
         12. Subjects who will commence or who are likely to commence treatment with non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) (other than aspirin), from screening until study&#xD;
             completion.&#xD;
&#xD;
         13. Any non-stable dosing of ongoing medication regimens throughout the study trial.&#xD;
&#xD;
         14. The subject has a three month prior history of regular alcohol consumption exceeding&#xD;
             an average weekly intake of &gt; 28 units (or an average daily intake of greater than 3&#xD;
             units) for males, or an average weekly intake of &gt; 21 units (or an average daily&#xD;
             intake of greater than 2 units) for females. 1 unit is equivalent to a halfpint&#xD;
             (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine; or a positive alcohol&#xD;
             breath test at the screening visit&#xD;
&#xD;
         15. A positive urine test for drugs of abuse (not related to known medications the subject&#xD;
             is taking, ie, codeine for pain management) or alcohol at screening or prior to study&#xD;
             medication administration.&#xD;
&#xD;
         16. Any other subject whom the Investigator deems unsuitable for the study (e.g., due to&#xD;
             either medical reasons, laboratory abnormalities, expected study medication&#xD;
             noncompliance, or subject's unwillingness to comply with all study-related study&#xD;
             procedures).&#xD;
&#xD;
         17. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions&#xD;
             known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).&#xD;
&#xD;
         18. Subjects with any acute infection, or significant trauma (burns, fractures).&#xD;
&#xD;
         19. Subjects who have donated more than 500 mL of blood within 56 days prior to the&#xD;
             initiation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amrita Ahluwalia</last_name>
    <role>Principal Investigator</role>
    <affiliation>QMUL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary University London</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, Arghandawi S, Pearl V, Benjamin N, Loukogeorgakis S, Macallister R, Hobbs AJ, Webb AJ, Ahluwalia A. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension. 2010 Aug;56(2):274-81. doi: 10.1161/HYPERTENSIONAHA.110.153536. Epub 2010 Jun 28. Erratum in: Hypertension. 2010 Sep;56(3):e37-9. Erratum in: Hypertension. 2017 Feb;69(2):e1.</citation>
    <PMID>20585108</PMID>
  </reference>
  <reference>
    <citation>Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, Rashid R, Miall P, Deanfield J, Benjamin N, MacAllister R, Hobbs AJ, Ahluwalia A. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008 Mar;51(3):784-90. doi: 10.1161/HYPERTENSIONAHA.107.103523. Epub 2008 Feb 4.</citation>
    <PMID>18250365</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gerry Leonard</name_title>
    <organization>Joint Research and Development Office, BLT/QMUL</organization>
  </responsible_party>
  <keyword>Nitrate</keyword>
  <keyword>Nitrite</keyword>
  <keyword>Vegetable</keyword>
  <keyword>Aortic stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

